Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Merger agrmnt [a]
Quarterly results
CC transcript
Inv. presentation
Director departure
Appointed director
AMICUS THERAPEUTICS, INC. (FOLD) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/28/2023 8-K Quarterly results
09/27/2023 8-K Quarterly results
08/08/2023 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates",
"2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this presentation may turn out to be wrong and can be affected by inaccurate..."
05/10/2023 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics, Inc. Consolidated Statements of Operations Three Months Ended March 31, 2023 2022 Net product sales $ 86,270 $ 78,715 Cost of goods sold 6,942 7,582 Gross profit 79,328 71,133 Operating expenses: Research and development 41,499 81,517 Selling, general, and administrative 73,957 58,116 Changes in fair value of contingent consideration payable 251 Loss on impairment of assets — 6,616 Depreciation and amortization 1,257 1,411 Total operating expenses 116,964 146,472 Loss from operations Other income: Interest income 2,199 133 Interest expense Other income 1,902 Loss before income tax Income tax benefit 287 Net loss attributable to common stockholders $ $ Net loss attributable to common stockholders per common share — basic and diluted $ $ Weighted-average common share...",
"2 Forward-Looking Statements This presentation contains"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this presentation may turn out to be wrong and can be affected by inaccurate ..."
11/16/2022 8-K Quarterly results
11/07/2022 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates",
"2 3 4 5"
09/14/2022 8-K Investor presentation
Docs: "2 3 4 5"
08/04/2022 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Second Quarter 2022 Financial Results",
"2Q22 Financial Results Conference Call & Webcast August 4, 2022 At the Forefront of Therapies for Rare Diseases"
05/09/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
11/09/2021 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Updates",
"2 3 4 5"
09/29/2021 8-K Investor presentation
Docs: "AMICUS THERAPEUTICS, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK",
"SPONSOR LETTER AGREEMENT This SPONSOR LETTER AGREEMENT , dated as of September 29, 2021, is made by and among ARYA Sciences Holdings IV, an exempted company incorporated in the Cayman Islands with limited liability , ARYA Sciences Acquisition Corp IV, an exempted company incorporated in the Cayman Islands with limited liability , Amicus GT Holdings, LLC, a Delaware limited liability company , each of Todd Wider, Leslie Trigg and Michael Henderson and each of Joseph Edelman, Adam Stone, Michael Altman and Konstantin Poukalov . ARYA, Amber GT and the Insiders shall be referred to herein from time to time collectively as the “Parties”. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Business Combination Agreement . WHEREAS, ARYA, A...",
"Schedule A",
"Schedule A",
"Schedule A",
"Agreement”), dated as of September 29, 2021, is among ARYA Sciences Acquisition Corp IV, a Cayman Islands exempted company and the other parties hereto identified as a “Holder” on the signature pages hereto . Capitalized terms used but not defined herein have the meanings assigned to them in the Business Combination Agreement dated as of the date hereof , among the Company, Amicus Therapeutics, Inc., a Delaware corporation , Amicus GT Holdings, LLC, a Delaware limited liability company , and Caritas Therapeutics, LLC, a Delaware limited liability company (“Caritas",
"LIMITED CONSENT AND AMENDMENT NO.1 TO LOAN AGREEMENT",
"Amendment to Employment and Confidentiality Agreements, by and between Amicus Therapeutics, Inc. and Hung Do",
"Amicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: “Caritas Therapeutics”"
08/05/2021 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Second Quarter 2021 Financial Results and Corporate Updates",
"2Q21 Financial Results Conference Call & Webcast August 5, 2021"
05/10/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
02/11/2021 8-K Quarterly results
11/05/2020 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates",
"2 3 4 5"
08/10/2020 8-K Quarterly results
05/14/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
03/02/2020 8-K Quarterly results
02/12/2020 8-K Quarterly results
01/13/2020 8-K Investor presentation
Docs: "Amicus Therapeutics Provides Full-Year 2020 Strategic Outlook and Financial Guidance",
"Presentation Materials - 38th Annual J.P. Morgan Healthcare Conference"
10/10/2019 8-K Investor presentation
Docs: "Amicus Therapeutics Announces Preliminary Third Quarter 2019 Revenue and Financial Outlook at 2019 Analyst Day",
"Amicus Therapeutics 2019 Analyst Day This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, business development plans and the projected revenues, sales, expenses and cash position for the Company. The inclusion of forward- looking statements should not be regarded as a representation by us that any of our plans or projections will be achieved. Any or all of the forward-looking statements in this pre..."
10/02/2019 8-K Quarterly results
08/08/2019 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Second Quarter 2019 Financial Results and Corporate Updates",
"August 8, 2019 Conference Call Presentation Materials"
08/01/2019 8-K Investor presentation
Docs: "Amicus Announces Positive Interim Clinical Data for AAV Gene Therapy in Children with CLN6 Batten Disease Study Shows Meaningful Impact on Motor and Language Function in Children with Fatal Neurologic Disease Evidence of Disease Stabilization in 7 of 8 Children with Data for up to 2 Years Post-Treatment Conference Call at 8:30 a.m. ET Today",
"Positive Interim Clinical Data from Ongoing Phase 1/2 Study in CLN6 Batten Disease August 1, 2019 Preliminary Data From Phase 1/2 Study in CLN6 Batten Disease"
07/08/2019 8-K Investor presentation
Docs: "Investor Presentation - July 2019"
05/29/2019 8-K Investor presentation
Docs: "Amicus Therapeutics and the University of Pennsylvania Announce Major Expansion of Gene Therapy Collaboration Exclusive Disease-Specific Worldwide Rights to Penn’s Next Generation Gene Therapy Technologies from the Wilson Lab for the Majority of Lysosomal Disorders Current Collaboration Extended to Include Three New Indications: Niemann-Pick Type C , Mucopolysaccharidosis Type IIIA and Mucopolysaccharidosis Type IIIB New Research Programs also Encompass 12 Additional Rare Diseases, including Rett Syndrome, Angelman Syndrome, Myotonic Dystrophy and Select Other Muscular Dystrophies Robust Amicus R&D Engine Created through Combination of Amicus Expertise in Protein Engineering with Penn’s Vector Technology, Translational Science, Manufacturing and Immunology Capabilities Amicus Now Positione...",
"Amicus Therapeutics Expands Gene Therapy Collaboration with University of Pennsylvania May 29, 2019 Expansion of Amicus and Penn Gene Therapy Collaboration"
05/14/2019 8-K Investor presentation
Docs: "S EXTRAORDINARY LAUNCH AT-GAA IN POMPE: POTENTIAL TO LEADING GENE THERAPY PORTFOLIO IN RARE SUCCESS BECOME STANDARD OF CARE METABOLIC DISEASES"
05/08/2019 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces First Quarter 2019 Financial Results and Corporate Updates",
"1Q19 Financial Results Conference Call"
04/30/2019 8-K Investor presentation
Docs: "Amicus Therapeutics Presents Positive Preclinical Pompe Disease Gene Therapy Data at American Society of Gene & Cell Therapy 22nd Annual Meeting Preclinical Studies Show Robust Uptake and Glycogen Reduction in Multiple Tissues, Including Brain and Spinal Cord Initial Validation for Collaboration Combining Amicus-Engineered Transgenes with Penn’s AAV Gene Therapy Technologies Significant and Broad New Amicus Platform Technology with Potential to Engineer Lysosomal Proteins to Enhance Targeting Ongoing Preclinical Studies to Confirm Clinical Candidate Selection in 2019 Conference Call Today at 8:30am",
"Preclinical Pompe Gene Therapy Results"
02/28/2019 8-K Quarterly results
02/05/2019 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy